Vaccines currently routinely recommended for pregnant women in the U.S. have not been shown to cause spontaneous abortion (SAb).
One recent randomized trial recruiting women at 17-34 weeks gestation , fourteen observational studies [2-15], two systematic reviews [16, 17], and one meta-analysis  have assessed the potential association between influenza vaccine and SAb or a related outcome, and none have found an association.
Steinhoff et al. enrolled 3,693 women in a randomized, placebo-controlled trial of influenza immunization during pregnancy in Nepal. Three participants in the placebo group (0.2%) and 5 in the vaccine group (0.3%) experienced miscarriage (risk ratio: 1.67; 95%CI: 0.40-6.98). 31 participants in the placebo group (1.7%) and 33 in the vaccine group (1.8%) experienced stillbirth (RR: 1.07; 95%CI: 0.66-1.73) . SAb was uncommon in this study given the age of study enrollment (17-34 weeks).
Chambers et al. followed 1,032 American and Canadian women between 2009 and 2012 in a prospective cohort study. 841 of these women received a pH1N1-containing vaccine during pregnancy. No increased risk of SAb was found (adjusted hazard ratio: 0.92; 95%CI: 0.31-2.72). 184 women vaccinated during the first trimester were included in an analysis that showed no increased risk of SAb (aHR: 0.84; 95%CI: 0.27–2.64) .
Chambers et al. also recruited 1,730 American and Canadian women between 2010 to 2014 as part of the cohort arm of the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS). 1,263 of these women were exposed to an influenza vaccine during pregnancy. There was no overall increase in risk of spontaneous abortion in first trimester exposure compared to the unexposed (aHR: 1.12; 95%CI: 0.47-2.65). Additionally, women who were vaccinated in the first trimester or any trimester were more likely than unvaccinated women to deliver a live born child (HR: 1.09; 95%CI 1.05, 1.13) .
Chavant et al. included 2,415 pregnant women vaccinated between November 2009 and March 2010 in France in a prospective cohort study. 97.6% of these women received a vaccine without adjuvant and 2.4% received an adjuvanted vaccine. They found that exposure to pH1N1-containing vaccines during pregnancy did not increase the risk of adverse pregnancy outcomes. 12 of the 2,246 pregnancies with known outcomes ended in spontaneous abortion. This 0.5% rate is below the base rate in the general population, observed at 10-15%; however, this is probably because only 3.9% of women in this study were vaccinated during their first trimester. Of the 92 women who were vaccinated during their first trimester, 5 experienced SAb .
Ma et al. included 226 pregnant women in China in a prospective cohort study. 122 of these women were immunized with pH1N1 vaccine. They found no difference in rates of spontaneous abortion between the vaccinated and unvaccinated group (0.8% vs 1.9%, respectively; P=0.470). However, the trimester of vaccination is not reported .
Oppermann et al. included 1,652 pregnant women in Germany in a prospective cohort study. 323 of these women were immunized with pH1N1 vaccine between September 2009 and March 2010. No increased risk of SAb was found (HR: 0.89; 95%CI: 0.36–2.19), although this was reported for all trimesters instead of just first trimester due to the limited number of first trimester vaccinations (n=55) and inability to adjust fully for confounders. The study also showed a higher rate of live births in vaccinated versus unvaccinated cohorts (97.2% vs. 87.9%) .
Pasternak et al. studied SAb among 35,408 Danish women using a national register based cohort study. 2,736 of these women were immunized with pH1N1 vaccine. No increased risk of SAb was found (HR: 1.11; 95%CI: 0.71-1.73). The risk of SAb specific to first trimester vaccinations was not reported. No increased risk of fetal death (either spontaneous abortion or stillbirth) was found among all vaccinated (HR: 0.79; 95%CI: 0.53-1.16) or first-trimester vaccinated women (HR: 0.96; 95%CI: 0.63-1.47) .
Tavares et al. included 267 pregnant women vaccinated in Britain during the 2009 flu season in a prospective cohort study. Of the 41 (15.4%) women vaccinated during the first trimester with known pregnancy outcomes, 3 ended in SAbs. They reported that this and all adverse events were consistent with the expected rates in their population .
De Vries et al. recruited 295 pregnant women who received pH1N1 vaccine for a cohort study in the Netherlands, of which 23 were vaccinated in their first trimester, and reported no increased risk of spontaneous abortions compared with the background rate .
Eaton et al. surveyed 5,365 pregnant women in Northern California by telephone, 40.7% of whom were vaccinated in the first trimester, and found no difference in SAb between pH1N1 and seasonal influenza vaccines. The risk of SAb specific to first trimester vaccinations was not reported .
Irving et al. found in a 2005-2006 case-control study in the U.S. no association with SAb during the 28 days after receipt of IIV (adjusted matched odds ratio: 1.23; 95%CI: 0.53-2.89). The study included 243 women with SAbs and 243 matched control women. 16 (7%) women with SAb and 15 (6%) matched control group women received influenza vaccine within the 28-day exposure window, all women included in the study were vaccinated before conception or in the first trimester .
Sammon et al. found in a retrospective cohort study in the U.K. a reduced risk of SAb and fetal death among pregnant women vaccinated against pandemic influenza. However, this may have been due to residual confounding that was unable to be measured, as suggested by sensitivity analyses .
Heikkinen et al. analyzed 4,508 pregnancy outcomes in a mixed prospective and retrospective cohort study in Argentina, Italy, and the Netherlands. Of the cohort, 2,295 (50.9%) women were vaccinated, 92 (4%) in their first trimester. They found no spontaneous abortions among women vaccinated against pandemic influenza, although this was attributed to the high average gestational age at enrollment .
Bratton et al. conducted a systematic review and meta-analysis. Their pooled estimate for SAb was not significant (relative risk: 0.91; 95%CI: 0.68-1.22). They did find that women who received influenza vaccine had a lower likelihood of stillbirth (RR: 0.73; 95%CI: 0.55-.96); even when restricted to pH1N1 vaccine (RR, 0.69; 95% CI, 0.53-0.90) .
Studies of HPV [20-30] and rubella [31-33] vaccines inadvertently given during pregnancy have not found an association with SAb or miscarriage. A systematic review of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy  and a meta-analysis of smallpox vaccination in pregnancy  also found no association with SAb. Studies examining a potential association with SAb among other vaccines are lacking.
Infection with wild-type influenza virus during pregnancy can cause life-threatening illness in pregnant women and increases the risk of SAb, as demonstrated during the 2009 influenza pandemic [36, 37]. Inflammation has been linked to pregnancy loss [38-40]. Although there is a brief inflammatory response in women (pregnant and non-pregnant women after influenza vaccination [41, 42], there is no evidence to support that the brief inflammation is sufficient to cause problems in pregnancy.
1. Steinhoff MC, Katz J, Englund JA, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 2017 Sep;17(9):981-989.
2. Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013 Oct 17;31(44):5026-32.
3. Chambers CD, Johnson DL, Xu R, et al. Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine 2016 Aug 17;34(37):4443-9.
4. Chavant F, Ingrand I, Jonville-Bera AP, et al. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza. Drug Saf 2013 Jun;36(6):455-65.
5. Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 2014 Nov 12;32(48):6463-8.
6. Ludvigsson JF, Ström P, Lundholm C, et al. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ 2015 Nov 16;351:h5585.
7. Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol. 2014 Sep;21(9):1282-7.
8. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012 Jun 22;30(30):4445-52.
9. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012 May 2;344:e2794.
10. Tavares F, Nazareth I, Monegal JS, et al. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine 2011 Aug 26;29(37):6358-65.
11. Irving SA, Kieke BA, Donahue JG, et al. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol 2013 Jan;121(1):159-65.
12. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. Dis JPLoS One 2012 Dec 20;7(12):e51734.
13. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012 Sep;207(3):177.e1-8.
14. de Vries L, van Hunsel F, Cuppers-Maarschalkerweerd B, et al. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Birth Defects Res A Clin Mol Teratol 2014 Oct;100(10):731-8.
15. Donahue, J. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink. Meeting of the Advisory Committee on Immunization Practices (ACIP). 2019. Atlanta, GA.
16. Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol 2012 Sep;207(3 Suppl):S38-46.
17. McMillan M, Porritt K, Kralik D, et al. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015 Apr 27;33(18):2108-17.
18. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015 Mar 1;60(5):e11-9.
19. Eaton A, Lewis N, Fireman B, et al. Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009-2010. Vaccine 2018 May 3;36(19):2733-2739.
20. Angelo MG, David MP, Zima J, B et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014 May;23(5):466-79.
21. Baril L, Rosillon D, Willame C, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine 2015 Nov 27;33(48):6884-91.
22. Bonde U, Joergensen JS, Lamont RF, Mogensen O. Is HPV vaccination in pregnancy safe? Hum Vaccin Immunother 2016 Aug 2;12(8):1960-1964.
23. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009 Dec;114(6):1170-8.
24. Forinash AB, Yancey AM, Pitlick JM, Myles TD. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy. Ann Pharmacother 2011 Feb;45(2):258-62.
25. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009 Dec;114(6):1179-88.
26. Goss MA, Lievano F, Buchanan KM, et al. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015 Jun 26;33(29):3422-8.
27. Panagiotou OA, Befano BL, Gonzalez P, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 2015 Sep 7;351:h4358.
28. Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes. N Engl J Med 2017 Mar 30;376(13):1223-1233.
29. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010 Mar 2;340:c712.
30. Vichnin M, Bonanni P, Klein NP, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015 Sep;34(9):983-91.
31. Badilla X, Morice A, Avila-Aguero ML, et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007 Sep;26(9):830-5.
32. Sato HK, Sanajotta AT, Moraes JC, et al. Rubella vaccination of unknowingly pregnant women: the São Paulo experience, 2001. J Infect Dis 2011 Sep 1;204 Suppl 2:S737-44.
33. Tookey PA, Jones G, Miller BH, Peckham CS. Rubella vaccination in pregnancy. CDR (Lond Engl Rev). 1991 Jul 19;1(8):R86-8.
34. Makris MC, Polyzos KA, Mavros MN, et al. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf 2012 Jan 1;35(1):1-14.
35. Badell ML, Meaney-Delman D, Tuuli MG, et al. Risks Associated With Smallpox Vaccination in Pregnancy: A Systematic Review and Meta-analysis. Obstet Gynecol 2015 Jun;125(6):1439-51.
36. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011 Jul;205(1):10-8.
37. Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol 2012 Sep;207(3 Suppl):S3-8.
38. Calleja-Agius J, Muttukrishna S, Pizzey AR, Jauniaux E. Pro- and antiinflammatory cytokines in threatened miscarriages. Am J Obstet Gynecol 2011 Jul;205(1):83.e8-16.
39. Lissauer D, Goodyear O, Khanum R, et al. Profile of maternal CD4 T-cell effector function during normal pregnancy and in women with a history of recurrent miscarriage. Clin Sci (Lond) 2014 Mar;126(5):347-54.
40. Christiansen OB, Nielsen HS, Kolte AM. Inflammation and miscarriage. Semin Fetal Neonatal Med 2006 Oct;11(5):302-8.
41. Christian LM, Iams JD, Porter K, Glaser R. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 2011 Nov 8;29(48):8982-7.
42. Christian LM, Porter K, Karlsson E, Schultz-Cherry S. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine 2015 Jun 26;33(29):3360-6.